Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Core Scientific, Inc. Tranche 2 Warrants (CORZZ) provides access to regulatory documents that explain how these warrants relate to Core Scientific’s common stock and broader capital structure. Core Scientific’s filings under the Exchange Act identify CORZZ as a class of warrants listed on the Nasdaq Global Select Market, each whole warrant exercisable for one share of Core Scientific common stock at a specified exercise price.
Through Forms 8-K and other filings, Core Scientific discloses material events affecting CORZZ, such as the satisfaction of trading price conditions that make tranche 2 warrants exercisable for a defined period. These filings describe the warrant terms, including exercise prices and the number of warrants outstanding, and may reference related press releases furnished as exhibits. Investors can review these documents to understand when and how CORZZ can be exercised and how many shares of common stock each warrant represents.
Filings also place CORZZ in the context of Core Scientific’s capital structure and corporate transactions. In connection with the company’s emergence from Chapter 11 reorganization, SEC disclosures outline the issuance of new common stock, tranche 1 warrants, tranche 2 warrants and other securities. Later 8-K filings describe an Agreement and Plan of Merger under which CoreWeave, Inc. is expected to acquire Core Scientific in an all-stock transaction. These documents explain how each share of Core Scientific common stock would convert into CoreWeave Class A common stock and how existing warrants, including tranche 2 warrants, would be adjusted into new warrants exercisable for CoreWeave shares based on an exchange ratio.
On Stock Titan, users can review real-time updates from EDGAR alongside AI-powered summaries that highlight key points from Core Scientific’s 8-Ks and other filings. These summaries help clarify the implications of warrant-related disclosures, merger terms, and other regulatory information without requiring readers to parse every technical detail. The filings page also surfaces information on registered securities, including CORZ, CORZW and CORZZ, so investors can see how the different instruments interact within Core Scientific’s disclosed capital structure.
Two Seas Capital LP, together with its general partner and CIO Sina Toussi, filed a Schedule 13D disclosing beneficial ownership of 19,122,842 Core Scientific (CORZZ) shares, or 6.3 % of the outstanding common stock. The position is held across the firm’s Strategic Fund, Global Fund and two managed accounts and includes 5.72 m options and 313.6 k warrants. Aggregate consideration for the shares, options and warrants totals roughly $133.9 million, funded with the working capital of the funds/accounts.
The filing signals an activist stance: on 7 Aug 2025 Two Seas issued an open letter stating it will vote against the proposed merger between Core Scientific and CoreWeave and intends to solicit proxies opposing the deal at the forthcoming special meeting. The filer may engage management and other shareholders, and could adjust its exposure through additional purchases, sales or hedging transactions—including swaps that reference a notional 500 k shares—depending on market conditions and strategic considerations.
Form 144 filed for Core Scientific, Inc. (CORZZ) discloses an intended sale of 7,759 common shares through Fidelity Brokerage Services on 06/25/2025 via the Nasdaq.
- Aggregate market value: $96,141.77
- Shares outstanding: 297,821,835 (sale represents ~0.003%)
- Source of shares: Restricted-stock vesting on 06/24/2025, received as compensation
- Seller’s recent activity: 57,921 shares sold in the prior three months, generating $675,328.06 in gross proceeds
The filing is a routine notice required under Rule 144 and does not, by itself, alter Core Scientific’s fundamentals. However, it documents additional insider liquidity actions that investors may monitor for context on executive trading trends.